About AVT
Browse Articles
Customer Services


Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies

Daniel J Tenney

Corresponding author name: Daniel J Tenney
Corresponding author e-mail: daniel.tenney@bms.com

Citation: Antiviral Therapy 2010; 15:529-535
doi: 10.3851/IMP1504

Date accepted: 16 December 2009
Date published online: 28 May 2010


Successful antiviral therapy results in cessation of disease progression and reversal of symptoms, and often can eliminate the virus infection. The emergence of virus with resistance to therapy, however, can abrogate these benefits; therefore, it is important to determine the pathways and frequency of resistance to antivirals. Often, resistance pathways can be elucidated in preclinical experiments through the isolation and characterization of resistant variants in cell culture or animals. For viruses without adequate cell culture systems, however, resistance pathways must await identification through analysis of isolates from patients failing therapy. Such is the case for antivirals used to treat chronic hepatitis B. Here, we detail the process used to define the pathways and frequency of resistance using genotypic and phenotypic assays during the development of entecavir, a novel therapy for chronic HBV infection. The scheme takes into account the need for rapid analysis of large numbers of clinical isolates through nucleotide sequencing and methods for phenotypic validation using cell culture and in vitro enzyme immunoassay formats.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.